The effect of pirfenidone on disease progression in asbestosis patients: a real-world Dutch cohort study
<b>Findings based on asbestosis patients treated between 2004 and 2024 reveal a modest reduction in the rate of FVC decline (mean (95% CI) difference 7.0 (-5.8-19.7) mL·month<sup>-1</sup>, p=0.22) and <i>D</i> <sub>LCO</sub> decline (0.11% (-0.19-0.41%), p=0.30) after starting pirfenidone</b> https://bit.ly/45fZ5TR.
Authors
- Ivo A. Wiertz (ORCID: https://orcid.org/0000-0003-3360-6263)
- Anne E. Wind
- Jelle Miedema (ORCID: https://orcid.org/0000-0002-7460-0805)
- Vincent van der Noort (ORCID: https://orcid.org/0000-0002-4910-4535)
- Illaa Smesseim (ORCID: https://orcid.org/0009-0003-0683-3804)
- Jan C. Grutters (ORCID: https://orcid.org/0000-0003-3670-8097)
- Bart Boerrigter
- Jacobus A. Burgers
Institutions
- Dutch Cancer Society (NL)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Medisch Centrum Haaglanden (NL)
- St. Antonius Ziekenhuis (NL)
- Oncode Institute (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1183/23120541.00845-2025
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00